DE Marco Vincenzo, Cerruto Maria Angela, D'Elia Carolina, Brunelli Matteo, Otte Oscar, Minja Anila, Luchini Claudio, Novella Giovanni, Cavalleri Stefano, Martignoni Guido, Artibani Walter
Urology Clinic, University of Verona, I-37126 Verona, Italy.
Department of Pathology, University of Verona, I-37126 Verona, Italy.
Mol Clin Oncol. 2014 Jul;2(4):575-580. doi: 10.3892/mco.2014.290. Epub 2014 May 8.
This study was conducted to test a new substaging system in a population of patients with stage T1 bladder cancer (BC) at diagnosis and assess its prognostic role in terms of disease progression and disease-specific survival (DSS). Patients with primary stage T1G3 urothelial carcinoma of the bladder were stratified according to the following models: i) T1a [the tumour does not infiltrate the muscularis mucosae-vascular plexus, (MM-VP)]; T1b (the tumour partially infiltrates the MM-VP); and T1c (the tumour infiltrates and invades the MM-VP). ii) T1m (diameter of tumour infiltrating the lamina propria ≤0.5 mm under a high-resolution microscope; and T1e (diameter of tumour infiltrating the lamina propria >0.5 mm). Age, gender, tumour size and multifocality were not found to be of statistical significance. Using the T1a/T1b/T1c system, patients with stage T1a disease exhibited a 5- and 10-year progression rate of 13.3 and 20%, respectively, without reaching statistical significance. Moreover, patients with stage T1a disease exhibited a 5- and 10-year DSS of 93.3 and 73.3%, respectively, which was higher compared to T1b and T1c but not statistically significant. Using the T1m/T1e system, patients with stage T1m disease exhibited a disease progression rate of 8.3 and 16.7% at 5 and 10 years, respectively, which was not statistically significant. Moreover, patients in group T1m presented with DSS rates of 91.7 and 83.3% at 5 and 10 years, respectively, which were higher compared to those in the T1e group (71.4 and 60.7%), although not reaching statistical significance. In conclusion, in our study, neither of the two substaging systems of stage T1 BC reached the prognostic conventional significance level for tumour progression or DSS.
本研究旨在对一群诊断为T1期膀胱癌（BC）的患者测试一种新的亚分期系统，并评估其在疾病进展和疾病特异性生存（DSS）方面的预后作用。原发性T1G3膀胱尿路上皮癌患者根据以下模型进行分层：i）T1a[肿瘤未浸润黏膜肌层-血管丛（MM-VP）]；T1b（肿瘤部分浸润MM-VP）；和T1c（肿瘤浸润并侵犯MM-VP）。ii）T1m（在高分辨率显微镜下肿瘤浸润固有层的直径≤0.5mm）；和T1e（肿瘤浸润固有层的直径>0.5mm）。未发现年龄、性别、肿瘤大小和多灶性具有统计学意义。使用T1a/T1b/T1c系统，T1a期疾病患者的5年和10年进展率分别为13.3%和20%，未达到统计学意义。此外，T1a期疾病患者的5年和10年DSS分别为93.3%和73.3%，高于T1b和T1c期，但无统计学意义。使用T1m/T1e系统，T1m期疾病患者在5年和10年的疾病进展率分别为8.
